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1. Introduction 
Polycystic ovary syndrome (PCOS) is an endocrine and metabolic heterogeneous disorder, 
with a likely genetic origin, influenced by environmental factors such as nutrition and 
physical activity. The main clinical features of PCOS are related to hyperandrogenism, such 
as hirsutism, acne and menstrual disorders (Moran et al., 1994; Azziz, et al., 2004; Carmina 
et al., 2006). PCOS is also associated with overweight or obesity (Azziz, et al., 2004), mainly 
abdominal adiposity (Moran et al., 1999). The etiology of PCOS is unknown. The genetic 
origin is based on the observation that PCOS is more frequent among the sisters and 
mothers of these patients (Lunde et al., 1989; Govind et al., 1999). Moreover, in a study done 
with twins, a higher correlation in the presence of PCOS is observed more in monozygotic 
than in dizygotic (Vink et al., 2006). Multiple genes related to the production of androgen, 
the function of the gonadotropin, the action of insulin and the regulation of energy have 
been evaluated. Although associations of some genes with clinical disorders of PCOS have 
been found, in specific regions and determined polymorphisms, the findings of studies and 
in different populations have not been consistent (Wood et al., 2003).  
The hypothesis of the origin of PCOS by environmental factors is based on the beneficial 
results observed by weight loss, and the worsening with increasing weight in these patients. 
The interaction of environmental factors of PCOS in women affected starts from their 
prenatal and postnatal life (Abbott et al., 2002). Food habits and lifestyle are also factors in 
the presentation and the development of PCOS. The influence of the environmental 
component of PCOS and its interaction with the genetic component has been less studied. 
Obesity plays an important role in the pathogenesis of PCOS, and the majority of patients 
with PCOS are overweight or obese; however, these disorders are not considered as 
diagnostic criteria for PCOS, since not all obese women present hyperandrogenism.  
2. Diagnosis 
The major criteria of PCOS, proposed in the consensus of the National Institutes of Health in 
Bethesda, M.D., were (in order of importance): a) hyperandrogenism and/or 
hyperandrogenemia, b) oligoovulation, c) exclusion of other known disorders, and d) possibly 
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the characteristic morphology of polycystic ovaries on ultrasound (Zawadzki & Dunaif, 1992). 
At the Rotterdam consensus, the presence of two out of the three following criteria was 
considered as diagnostic for PCOS: a) oligoovulation or anovulation, b) clinical and/or 
biochemical signs of hyperandrogenism, and c) polycystic ovaries by ultrasound, after 
exclusion of other related disturbances (ESHRE/ASRM-Sponsored PCOS Consensus, 2004). 
The Androgen Excess and PCOS Society considers as PCOS: hyperandrogenism (hirsutism 
and/or hyperandrogenemia), ovarian dysfunction (oligo-anovulation and/or polycystic 
ovaries), and the exclusion of other androgen excess or related disorders (Azziz, et al., 2006). 
3. Phenotypes 
Overweight and obesity are not considered for PCOS phenotypes (Azziz, et al., 2006). 
Phenotypes of PCOS patients can be classified as follows: A) hyperandrogenism, oligo-
anovulation and polycystic ovaries by ultrasound; B) hyperandrogenism and oligo-
anovulation (and normal appearance of the ovaries by ultrasound); C) hyperandrogenism and 
polycystic ovaries by ultrasound (with regular ovulatory menstrual cycles); and D) oligo-
anovulation and polycystic ovaries by ultrasound (without hyperandrogenism). The National 
Institutes of Health criteria recognizes A and B phenotypes. The Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group accepts all these phenotypes. The AE-PCOS 
Society admits A, B and C phenotypes (Table 1). However, each one of the phenotypes can be 
subdivided considering the presence of obesity, when body mass index is (BMI) ≥ 27.  
 
Table 1. Phenotype classification in 172 patients with polycystic ovary syndrome taking into 
account obesity (body mass index ≥ 27) to subdivide each group. The frequencies of 
different phenotypes are unpublished data yet, Moran C, 2011.  
4. Prevalence of PCOS and/or obesity 
Polycystic ovary syndrome (PCOS) affects 4-7% of women in reproductive age 
(Knochenhauer et al., 1998; Diamanti-Kandarakis et al., 1999; Asuncion et al., 2000; Moran et 
al., 2010). It is considered one of the most frequent endocrine disorders in women of 
reproductive age (Moran et al., 2010). It is noteworthy that PCOS affects 60-80% of the 
patients with hyperandrogenism (Table 2) (Moran et al., 1994; Azziz et al., 2004, Carmina et 
al., 2006). Overweight or obesity affects approximately 60-80% of PCOS patients (Azziz et 
al., 2004).  
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Table 2. Classification of hyperandrogenism in women. PCOS: polycystic ovary syndrome, 
CAH: Congenital adrenal hyperplasia, HAIRAN: Hyperandrogenisim, insulin resistance 
and acanthosis nigricans. *Hyperandrogenic overweight or obese patients with regular 
menstrual cycles. Taken from 1Moran et al., Archives of Medical Research, 1994; 2Azziz et al., 
The Journal of Clinical Endocrinology & Metabolism, 2004; 3Carmina et al., The Journal of Clinical 
Endocrinology & Metabolism, 2006.  
5. Clinical presentation in obese and nonobese PCOS patients 
It has been reported that obese PCOS patients have a greater prevalence of some clinical 
manifestations, such as hirsutism and menstrual disorders (Kiddy et al., 1990); however, other 
studies have not found differences (Singh et al., 1994). The discrepancies between these studies 
may be the result of different diagnostic criteria used to classify obesity and PCOS. 
6. Role of obesity in the pathophysiology of PCOS  
6.1 Gonadotropic dysfunction 
The main pathophysiological components of PCOS are gonadotropic dysfunction and 
insulin resistance (Dale et al., 1992; Fulghesu et al., 1999; Moran et al., 2003). It has been 
found that both of these components are related to BMI. 
Dissociation of luteinizing hormone (LH) to follicle-stimulating hormone (FSH) higher in 
PCOS patients with normal weight than in obese PCOS patients has been observed in some 
studies (Dale et al., 1992); although this observation has not been found in other studies 
(Fulghesu et al., 1999; Moran et al., 2003) (Table 3).  
6.2 Insulin resistance 
PCOS is associated to metabolic disorders like insulin resistance (Matteini et al., 1982; Chang 
et al., 1983; Shoupe et al., 1983; Pasquali, et al., 1983), becoming a risk factor for development 
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of carbohydrate intolerance and type 2 diabetes mellitus (Legro et al., 1999; Ehrmann et al., 
1999). Insulin resistance appears in women with PCOS with suitable weight (Chang et al., 
1983), and overweight or obesity (Moran et al., 2003), but is more frequent and of greater 
magnitude when there is obesity (Dunaif et al., 1989; Moran et al., 2003). The insulin 
resistance is approximately two-fold that of non obese PCOS patients (Table 3) (Moran et al., 
2003). The magnitude of overweight and obesity is directly related to insulin resistance in 
PCOS patients (Figure 1) (Moran et al., 2003). 
 
Table 3. Frequency of pathophysiologic components of polycystic ovary syndrome (PCOS). 
All the determinations were performed in one sample in fasting conditions. *Statistically 
significant difference (P< 0.01). From Moran et al, Fertility and Sterility, 2003. 
 
Fig. 1. Relationship between body mass and insulin resistance in patients with polycystic 
ovary syndrome. Modified from Moran et al, Fertility and Sterility, 2003. 
6.3 Body fat distribution  
Obesity is associated mainly to abdominal adiposity in PCOS patients (Moran et al., 2003). It 
is important to recognize the presence of obesity and its upper body distribution or 
abdominal adiposity, which changes in accordance to race and geographical distribution 
(ESHRE/ASRM-Sponsored PCOS Consensus, 2004). The upper body adiposity is related to 
insulin resistance in PCOS patients (Figure 2) (Moran et al., 2003). To this matter, upper 
body adiposity has been found to be associated with a higher percentage of anovulation in 
comparison to lower body adiposity (83% vs. 65%, respectively) (Moran et al., 1999). 
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Fig. 2. Relationship between body fat distribution and insulin resistance in patients with 
polycystic ovary syndrome. Modified from Moran et al, Fertility and Sterility, 2003. 
6.4 Ovarian morphology of polycystic ovaries 
There is some evidence indicating the relationship of anthropometric and hormonal 
measures with the characteristic polycystic ovarian morphology. On analyzing the 
anthropometric variables of PCOS patients, BMI is significantly greater in PCOS patients 
with a characteristic polycystic ovary image than in those without it; also, it has been found 
that the hip perimeter is significantly greater in PCOS patients with characteristic image of 
polycystic ovary than in those without this ultrasonographic morphology (Tena et al., 2011). 
In addition, PCOS patients with the polycystic ovarian morphology by ultrasound present 
greater levels of testosterone than patients without it.  
6.5 Adipocytokines  
Patients with PCOS-in comparison to control women–present lower serum levels of 
adiponectin but not of leptin. A decrease was observed in the expression of the ribonucleic 
acid (RNA) messenger of adiponectin in the subcutaneous and visceral adipose tissue, while 
that of leptin has been found significantly less only in the subcutaneous adipose tissue. Also, 
it has been observed an inverse relationship among adiponectin and leptin expression and 
the measurement of subcutaneous and visceral adipose tissue by ultrasound (Carmina et al., 
2008). Other authors have reported that obese PCOS but not normal weight PCOS patients 
have significantly lower adiponectin levels than control women (Olszanecka-Glinianowicz 
et al., 2011).  
6.6 Metabolic syndrome 
The prevalence of metabolic syndrome is higher in PCOS patients than in control women (47% 
vs. 4%, respectively) (Dokras et al., 2005). Free fatty acids, total cholesterol and low density 
lipoprotein cholesterol are higher in obese PCOS patients than in non obese PCOS patients 
(Holte et al., 1994). Both PCOS and obesity are associated with dyslipidemia and endothelial 
dysfunction that increase the cardiovascular risk. Although metabolic disorders prevail in the 
climacteric period, the risk of metabolic syndrome is high even at reproductive age.  
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Both PCOS and obesity induce an increase in serum inflammatory cardiovascular risk 
markers (Samy et al., 2009). Increased C-reactive protein, interleukin-6 and tumor necrosis 
factor alpha have been reported in obese PCOS patients with respect to control women; in 
addition, these markers have correlated with BMI and insulin resistance (Samy et al., 2009). 
Fatty liver has been reported present until 40% of PCOS patients associated to higher BMI, 
abdominal obesity and worse lipid profile (Ma et al., 2011). The pathogenetic relation among 
PCOS, obesity, metabolic and cardiovascular disease is controversial. A low-grade chronic 
inflammation has been proposed as the potential cause of the long-term complications of 
PCOS (Repaci et al., 2011).  
7. Androgen production in obese and non obese PCOS patients 
In normal women, androstenedione and testosterone are produced mainly in the ovaries, 
while dehydroepiandrosterone and dehydroepiandrosterone sulfate are secreted 
predominantly in the adrenals (Parker, 2006). The ovaries produce approximately 50% of 
testosterone and androstenedione while the adrenals 70% of dehydroepiandrosterone and 
almost all dehydroepiandrosterone sulfate (Longcope, 1986). Dehydroepiandrosterone is the 
main precursor of androgens and estrogens, and it is sulfated by the enzyme SULT2A1 in 
adrenals (Miller et al., 2006).  
Controversy exists about the effect of obesity on serum androgen concentrations in PCOS. 
Some investigators have reported that testosterone and androstenedione levels are similar in 
obese and non obese PCOS patients (Dale et al., 1992; Dos Reis et al., 1995). However, it is 
well known that obesity generates a decrease in the sexual hormone-binding globulin 
(SHBG), and therefore an increase in the free androgens (Kiddy et al., 1990; Holte et al., 
1994). Other studies have found that obesity generates an increase of testosterone levels in 
PCOS patients (Figure 3) (Holte et al., 1994; Acien et al., 1999, Moran et al., 2008). In contrast, 
dynamic studies have shown a decrease in androstenedione levels in obese PCOS patients 
(Dunaif et al., 1988; Moran et al., 2008). 
Hyperandrogenism may be of ovarian or adrenal origin (Rosenfield et al., 1972). 
Participation in PCOS by the increment of dehydroepiandrosterone sulfate is found in 22-
25% of PCOS patients (Moran et al., 1999). However, some studies have found frequencies 
of hyperandrogenism due to dehydroepiandrosterone sulfate of 48-52% in different 
populations (Carmina et al., 1992). Hyperandrogenic patients with higher adrenal androgen 
excess have been informed to be leaner, younger and present more hirsutism than patients 
with lower levels of these steroids (Moran et al., 1999).  
8. Obesity in pregnant PCOS patients 
Due to obesity and PCOS determine independently a deleterious effect on pregnancy and 
reproductive outcome, their impact of both conditions together are expectedly adverse in 
pregnant women and their fetuses. Obese patients with PCOS are characterized by a more 
severe hyperandrogenic and metabolic state, more irregular menses, less ovulatory cycles 
and lower pregnancy rates, compared with normal weight PCOS patients; the importance of 
obesity in the pathogenesis of PCOS is evidenced by the efficacy of weight loss to improve 
metabolic alterations, to decrease hyperandrogenism, to increase ovulatory menstrual cycles 
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and to improve fertility (Pasquali et al., 2006). The information with respect to the impact of 
obesity in hormonal and metabolic factors during intrauterine life is scarce yet.  
 
Fig. 3. Values of total testosterone and androstenedione in obese and nonobese patients with 
PCOS and in control women. Box-and-whiskers plots of basal levels of androgens. The line 
within each box represents the median. Upper and lower boundaries of each box indicate 
75th and 25th percentiles, respectively. The whiskers (above and below) show the upper and 
lower adjacent values, respectively. The levels of testosterone were significantly greater in 
the obese patients with PCOS compared with non obese PCOS patients and controls. Also, 
the testosterone levels were significantly greater in non obese PCOS patients than in control 
women. There were no significant differences in the levels of androstenedione. Modified 
from Moran et al, Fertility and Sterility, 2008. 
9. Treatment of obesity and metabolic abnormalities in PCOS patients 
The current management of PCOS has to attend to the clinical, hormonal and metabolic 
abnormalities. The change in PCOS concept of the treatment is that it is not considered only 
a reproductive problem but also an endocrine and metabolic disorder that requires a long 
term follow-up. Furthermore, the treatment must address specific problems that affect 
PCOS patients, such as hirsutism, acne, overweight or obesity, menstrual disorders and 
infertility (Moran et al., 1994; Azziz et al., 2004, Carmina et al., 2006).  
9.1 Modifications in life style 
Weight loss is the principal recommendation as the first line of treatment in obese women 
with PCOS. The treatment of obesity in PCOS must include nutritional counselling in food 
habits and lifestyle (Kiddy et al., 1992; L.J. Moran et al., 2003). The weight loss partially 
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ameliorates hirsutism (Pasquali et al., 1989; Kiddy et al., 1992), regularizes menstrual cycles 
and ovulation, as well as improves the endocrine and metabolic abnormalities (Pasquali et 
al., 1989; Kiddy et al., 1992; Guzick et al., 1994; Holte et al., 1995).  
9.1.1 Food habit 
There is a known beneficial effect of the decrease of body weight and a worsening with the 
increase of excess weight in PCOS patients. It has been observed that some patients with 
PCOS can present menstrual cycles and ovulation after having reduced at least 5 % of her 
body weight (Kiddy et al., 1992). The studies on food habits in patients with PCOS have 
shown that the most important thing is caloric restriction, achieving a reduction of about 7% 
body weight, and that there is no difference in the metabolic results changing the 
composition of the diet (L.J. Moran et al., 2003). However, it has been reported that low 
glycemic index diet improved insulin sensitivity and menstrual periodicity more than the 
conventional healthy diet in PCOS patients (Marsh, 2010).  
9.1.2 Exercise 
Physical activity has been shown lower in PCOS patients than in control women (Write et 
al., 2004). The changes in lifestyle that incorporate an increase of physical activity and 
limited caloric intake have been beneficial in some studies. Regular physical activity is an 
important component to support the reduction of long-term weight; the results are minimal 
with exercise alone (Hoeger, 2008). An increase in physical activity is recommended for 
women with obesity and PCOS, as long as cardiovascular and orthopaedic limitations are 
considered (Moran et al., 2006).  
9.2 Insulin sensitizer agents 
9.2.1 Metformin 
The temporary use of metformin is considered, as a coadjutant of diet and exercise to control 
insulin resistance, especially in patients with obesity and glucose intolerance (Velazquez et 
al., 1994; ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008). 
Nevertheless, the duration of this therapy is unknown yet. The metformin diminishes the 
hepatic glucose synthesis, inhibiting the gluconeogenesis; it also increases the glucose use by 
the striated muscle (Kirpichnikow et al., 2002).  
Administration of metformin to obese PCOS patients reduces the levels of circulating 
insulin, the activity of the complex P450c17 and the ovarian secretion of androgens 
(Nestler & Jakubowicz, 1996). Metformin can reduce the circulating androgen levels, may 
normalize the menstrual cycles and improve ovulation (Velazquez et al., 1994). The 
combined use of metformin and clomiphene has been recommended for PCOS patients with 
overweight or obesity who present more insulin resistance, especially in those refractory to 
the clomiphene (ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008). 
Metformin has contraindications and some side effects (Lord et al., 2003). It must not be 
used in patients with renal insufficiency, hepatic malfunction, congestive heart failure and 
those with a history of alcoholism. It is important to take into account that metformin in rare 
cases can produce lactic acidosis; it is necessary to evaluate renal function before and 
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periodically during its administration, even though this complication is extremely rare. The 
gastrointestinal adverse effects, mainly nausea and diarrhoea, affect 10 to 25% of the 
patients taking metformin. The undesirable effects are transitory; however, in a minority of 
patients these can cause discontinuation of the treatment. To minimize adverse effects, 
metformin must be administered gradually. Metformin can induce bad absorption of 
vitamin B12 in patients who use it for long periods of time, even though this effect is very 
rare. In patients who wish to use contraception, it is necessary to add an oral contraceptive 
while still taking metformin. In those cases of hirsutism it is possible to add antiandrogens, 
oral contraceptives or both. 
9.2.2 Thiazolidindiones 
Among thiazolidindiones are troglitazone, rosiglitazone and pioglitazone, which improve the 
sensitivity of the insulin in the liver, striated muscle and adipose tissue; they also reduce the 
concentrations of insulin and circulating androgens (Lord et al., 2003). The use of troglitazone 
was ceased in research protocols conducted in PCOS patients because of hepatotoxicity 
reports. Although rosiglitazone and pioglitazone are as effective as metformin to treat insulin 
resistance in PCOS patients, it appears they are less effective to lower BMI than metformin. 
These drugs have been used less due to the concern of their use during pregnancy.  
9.3 Drugs for obesity and dyslipidemia 
Drugs to control obesity have been used in obese patients with PCOS, although few studies 
exist to support this therapeutic approach. It is known that orlistat blocks the absorption of 
intestinal fat (Jayagopa et al., 2005), and sibutramine suppresses the appetite (Sabunku et al., 
2003); both favor weight loss independently from the androgen excess and insulin 
resistance. It is important to take into account that these treatments must not be considered 
first line treatments for obesity in patients with PCOS.  
There are little evidences that statins, apart from specific action on lipid profile decreasing 
total cholesterol and low density lipoprotein cholesterol, can reduce serum androgens, 
inflammatory markers and insulin resistance (Banaszewska et al., 2009; Sathyapalan et al., 
2009, Raja-Khan et al., 2011). However, statins and bezafibrate (Hara et al., 2010) should only 
be used in women with PCOS who meet current indications for those treatments.  
9.4 Bariatric surgery 
Few studies exist on the impact of bariatric weight loss surgery on manifestations of PCOS 
in patients with morbid obesity. The initial results of bariatric surgery in patients with 
morbid obesity and PCOS seem encouraging, since aside from the weight reduction there is 
a decrease of hyperandrogenemia, hirsutism, insulin resistance and restoration of menstrual 
cycles and ovulation (Escobar-Morreale et al., 2005). 
10. Research of obesity and PCOS for the future 
The differences in the hormonal and metabolic profile, as well as the different response to 
treatment of obese and non obese PCOS patients suggest that obesity has to be considered as 
a secondary characteristic for the PCOS phenotype classification in prospective trials.  
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The intrauterine milieu in pregnancy and the reproduction outcome of PCOS patients with 
overweight or obesity are important topics for research in prospective studies.  
PCOS and obesity induce an increase in serum inflammatory cardiovascular risk markers. 
The precise mechanisms underlying these associations require additional studies, to 
determine the relative contribution of different factors on cardiovascular disease.  
11. Summary 
PCOS is associated with overweight or obesity, mainly abdominal adiposity; approximately 
80% of patients with PCOS are either overweight or obese. The insulin resistance, present in 
most of patients with obesity and/or PCOS, is a risk factor to develop carbohydrate 
intolerance and type 2 diabetes mellitus. Insulin resistance is higher and of greater 
magnitude in obese than non obese PCOS patients. A decrease in the synthesis of SHBG has 
been found, and therefore an increase in the free androgens in obese PCOS patients. It has 
been observed in some studies that obese PCOS patients present an increase of testosterone 
levels and a decrease in androstenedione. Weight loss is the main recommendation in obese 
PCOS patients. The treatment of obesity in PCOS must include nutritional counselling in 
food habits and life style. An increase in physical activity is recommended for PCOS 
patients. The temporary use of metformin may be useful, in conjunction with diet and 
exercise, to control insulin resistance, especially in PCOS patients with obesity and glucose 
intolerance. The combined use of metformin and clomiphene for ovulation induction has 
been suggested mainly in patients with overweight or obesity, who present more insulin 
resistance, refractory to the clomiphene alone. Drugs used to control obesity, as orlistat or 
sibutramine, must not be considered as the first choice for obesity in patients with PCOS. 
The initial results of bariatric surgery in patients with morbid obesity and PCOS seem 
encouraging, since aside from the weight reduction, a decrease of hyperandrogenemia, 
insulin resistance, hirsutism, and the restoration of menstrual cycles and ovulation have 
been observed. Obesity decreases or delays the results of several treatments for infertility 
such as the administration of clomiphene, gonadotropins and ovarian drilling. The 
differences in the hormonal and metabolic profile, as well as the different response to 
treatment between obese and non obese PCOS patients suggest that obesity has to be 
considered as a secondary characteristic for the determination of PCOS phenotypes.  
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